More Hoosiers Facing Alzheimer’s Diagnoses As Caregiver Costs Rise
A new study showed costs are rising for caring for Hoosiers with Alzheimer’s disease and forms of dementia.
Read MoreTag Archives: Alzheimer’s disease
EU Committee Reject Lilly Alzheimer’s Drug
The European Medicines Agency, citing the potentially dangerous risk of brain swelling and hemorrhage, rejected Eli Lilly and Co.’s new Alzheimer’s disease drug Kisunla.
Read More
New Tests Bring Hope To Indiana Alzheimer’s Patients, Families
New research directed at earlier detection of Alzheimer’s disease has produced a more promising method for diagnosis.
Read More
New Care Model Allows For Care For Unpaid Alzheimer’s Caregivers
Indiana doctors have created an Alzheimer’s disease and related dementia care model that helps unpaid family caregivers as much as it helps the patient.Â
Read More
Alzheimer’s Association Hosts Caregiver Support Groups
INDIANAPOLIS — The Alzheimer’s Association offers open support groups to provide caregivers with the opportunity to share their experiences and receive support from others living with Alzheimer’s disease. Feeling connected on the journey of Alzheimer’s disease can be an integral part of coping with the diagnosis and becoming … Read More
First Patient Enrolled In Lilly, AstraZeneca Alzheimer’s Drug Study
Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown … Read More
Lilly Moving Forward With Study On Alzheimer’s Drug
Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer’s disease. Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional … Read More
Eli Lilly Announces Alzheimer’s Drug Testing Results
Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials … Read More